Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris (NASDAQ: VTRS) announced that the U.S. District Court for Kansas dismissed a lawsuit filed by KPH Healthcare Services, asserting claims against Mylan and Pfizer over EpiPen products. The court ruled that KPH lacked legal standing, allowing the case to be dismissed entirely, with a possibility for KPH to file a limited amended complaint within 30 days. Viatris expressed satisfaction with the ruling, emphasizing its commitment to legal compliance and willingness to defend against future proceedings.
Viatris Inc. (NASDAQ: VTRS) will announce its second quarter 2021 financial results on August 9, before the U.S. market opens. A webcast featuring CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will be held at 10 a.m. ET the same day. Investors can listen to the call live via the company's investor website or by phone. Established in November 2020, Viatris focuses on providing access to medicines and healthcare solutions globally, maintaining a portfolio of over 1,400 approved molecules.
Viatris (NASDAQ: VTRS) will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 10:30 a.m. ET. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will discuss the company and address queries. Interested individuals can access the live webcast at investor.viatris.com, with an archived version available later. Viatris aims to empower global health through access to over 1,400 medicines and operates in 165 countries.
Viatris Inc. (VTRS) reported Q1 2021 financial results with total revenue at $4.4 billion, reflecting a 70% increase year-over-year. The company faced a U.S. GAAP net loss of $1.0 billion, while adjusted EBITDA stood at $1.6 billion. Free cash flow reached $799 million. The Board declared a quarterly dividend of $0.11 per share, payable June 26, 2021. Viatris anticipates achieving approximately $500 million in synergies and has generated $163 million from new product revenue, reiterating its positive outlook for the year.
Summary not available.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 9:10 a.m. ET. CEO Michael Goettler and CFO Sanjeev Narula will discuss the company and answer questions. A live webcast will be available at investor.viatris.com, with an archived version accessible later. Formed in November 2020 from Mylan and Pfizer's Upjohn business, Viatris serves over 165 countries and offers a diverse portfolio of over 1,400 approved medicines.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the BofA Securities 2021 Health Care Conference on May 11, 2021, at 8 a.m. ET. President Rajiv Malik and CFO Sanjeev Narula will address questions regarding the company. Interested parties can access a live webcast at investor.viatris.com, with an archived version available afterward. Viatris, formed in November 2020, aims to provide global access to a diverse portfolio of over 1,400 medicines targeting various health conditions, supporting sustainable healthcare.
Viatris Inc. (NASDAQ: VTRS) will release its first quarter 2021 financial results on May 10, 2021, prior to the U.S. market opening. A webcast will follow at 10 a.m. ET to discuss these results, accessible at investor.viatris.com or via phone at 855.493.3607. Viatris formed in November 2020, merging Mylan and Pfizer's Upjohn. The company aims to improve global health access with a portfolio of over 1,400 approved molecules and operates in over 165 countries.
On March 8, 2021, Viatris (NASDAQ: VTRS) and Kindeva Drug Delivery announced the FDA granted tentative approval for the first generic version of Symbicort, budesonide/formoterol fumarate dihydrate. This approval, however, comes amid ongoing patent litigation with AstraZeneca, preventing immediate commercial launch. Despite significant U.S. sales of Symbicort, Viatris has not projected any revenue from this product for 2021. This milestone reflects the partnership's strength and Viatris’ commitment to advancing access to respiratory treatments.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 p.m. ET. Key executives including CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will address questions regarding the company. A live webcast can be accessed at investor.viatris.com, with an archived version available afterward. Viatris, formed in November 2020 from Mylan and Pfizer's Upjohn business, aims to enhance global healthcare access.